Onkure Therapeutics to advance next-generation PI3Kα pan-mutant programs

AI Briefing

• – Onkure Therapeutics raises $150M for PI3Kα inhibitor programs.
• – Next-generation PI3Kα pan-mutant selective inhibitor candidates for breast cancer and vascular anomalies.
• – Preclinical and clinical development plans for the new candidates.